Insulet (PODD) EBT Growth (3y) (2013 - 2026)
Insulet (PODD) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -2.34% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 20.27% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 5.75% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 35.51% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 23.63% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 25.85% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 6.73% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 89.20% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 17.92% |
| 10 | Insulet | 10.27 Bn | 9.74 Bn | 562.60 Mn | 60.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.89% |
| Mar 31, 2026 | 66.23% |
| Dec 31, 2025 | 84.56% |
| Sep 30, 2025 | 186.61% |
| Jun 30, 2025 | 40.72% |
| Mar 31, 2025 | 18.05% |
| Dec 31, 2024 | 49.41% |
| Sep 30, 2024 | 76.02% |
| Jun 30, 2024 | 56.04% |
| Mar 31, 2024 | 467.74% |
| Dec 31, 2023 | 98.59% |
| Sep 30, 2023 | 58.84% |
| Jun 30, 2023 | 17.88% |
| Mar 31, 2023 | 125.47% |
| Dec 31, 2022 | 48.57% |
| Sep 30, 2022 | -92.94% |
| Jun 30, 2022 | -175.89% |
| Mar 31, 2022 | 84.04% |
| Dec 31, 2021 | 45.42% |
| Sep 30, 2021 | 101.68% |